Mizuho Medy: Quarterly Financial Results Summary for the First Quarter of the Fiscal Year Ending December 2026 (Japanese GAAP) (Non-Consolidated)

JPXMay 12 23:00 ET · Announcements

Mizuho Medy 1Q Parent Net Y601.00M Vs Net Y777.00M

Dow JonesMay 12 23:00 ET

INPEX, Matsumotokiyoshi, Takeda Pharmaceutical, and Nippon Steel (13th) (131A-5997)

※The above calendar is only a tentative schedule and is subject to change based on company circumstances. --------------------------------------- May 13 (Wed) <131A> CCN Group <143A> Isin <1515> Nippon Steel Mining <1518> Mitsui Matsushima HD <1605> INPEX <1662> Petroleum Resources <1663> K&O Energy <1726>

Fisco JapanMay 12 17:30 ET

Audit Consideration 25/12 = Mizuho Medy: Revenue for which the collection deadline does not fall due by the end of the fiscal period.

Submitter: Mizuho Medy Co., Ltd. Submission Date and Time: March 26, 2026, 09:10 Document Submitted: Annual Securities Report Fiscal Year: 49th term (From January 1, 2025, to December 31, 2025) <Key Audit Matters for Individual Financial Statements: 1 item> ▼Recognition of revenue for which the collection deadline has not arrived by the end of the fiscal year <First two sentences> Mizuho Medy Co., Ltd. (hereinafter referred to as “the Company”) is engaged in the manufacturing of in vitro diagnostic pharmaceuticals and distributes its products domestically and internationally.

Jiji PressMar 25 20:13 ET

Mizuho Medy: Confirmation letter

EDINETMar 25 20:12 ET · Announcements

Mizuho Medy: Securities Report – Fiscal Year 49 (January 1, 2025 – December 31, 2025)

EDINETMar 25 20:10 ET · Announcements